Bionano Genomics (NASDAQ: BNGO) awards CSO 54,000 options vesting from 2027

Rhea-AI Filing Summary

Bionano Genomics, Inc. reported an equity award to Chief Scientific Officer Alex Reid Hastie of a stock option covering 54,000 shares of common stock at an exercise price of $1.12 per share, expiring August 2, 2036. Twenty-five percent vests August 2, 2027, with the balance vesting in 36 monthly installments, and the report replaces an earlier erroneous initial ownership statement filed August 5, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hastie Alex Reid

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	54,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 54,000 shares (Direct)

Footnotes (2)

1. F1. 25% of the shares subject to the option shall vest and become exercisable on August 2, 2027, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from August 2, 2027, subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each such applicable vesting date.
2. F2. The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.

Key Figures

Stock options granted: 54,000 shares Exercise price: $1.12 per share Option expiration: August 2, 2036 +4 more

7 metrics

Stock options granted 54,000 shares Stock option award to CSO Alex Reid Hastie on August 3, 2026

Exercise price $1.12 per share Conversion or exercise price of the reported stock option

Option expiration August 2, 2036 Expiration date of the stock option award

Initial vesting portion 25% of shares Portion that vests and becomes exercisable on August 2, 2027

Remaining vesting schedule 36 monthly installments Equal monthly vesting installments measured from August 2, 2027

Options held after grant 54,000 shares Total derivative securities following the reported transaction

Prior ownership statement date August 5, 2026 Earlier initial ownership statement that this report replaces

Key Terms

Stock Option (Right to Buy), Continuous Service, 2018 Plan, vesting

4 terms

Stock Option (Right to Buy) financial

"security title listed as "Stock Option (Right to Buy)""

Continuous Service financial

"subject to the Reporting Person's Continuous Service through each applicable vesting date"

2018 Plan financial

"as defined in the Company's 2018 Plan"

vesting financial

"the remaining shares shall vest in a series of 36 successive equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 05:28 PM Accepted by SEC EDGAR 08/05/2026 - 05:26 PM Learn about SEC filing dates

FAQ

What equity award did Bionano Genomics (BNGO) grant to its Chief Scientific Officer?

Bionano Genomics granted CSO Alex Reid Hastie a stock option for 54,000 shares of common stock. The option has an exercise price of $1.12 per share, giving him the right to buy shares at that price before the option expires in 2036.

How does the 54,000-share option for BNGO’s CSO vest over time?

The option vests with 25% of the shares becoming exercisable on August 2, 2027. The remaining 75% vests in 36 equal monthly installments thereafter, conditioned on Alex Reid Hastie continuing to provide service through each vesting date.

When does the new stock option granted by Bionano Genomics (BNGO) to its CSO expire?

The granted stock option expires on August 2, 2036. After this expiration date, any unexercised portion of the 54,000-share option will lapse, and Alex Reid Hastie will no longer be able to purchase shares under this award.

What prior ownership report does this BNGO insider transaction replace?

The report states that it replaces an initial ownership statement filed August 5, 2026 that was erroneous. This new disclosure is intended to supersede that earlier filing and present the correct stock option information for Alex Reid Hastie.

Was the BNGO CSO’s stock option grant made under a Rule 10b5-1 trading plan?

The disclosure indicates the Rule 10b5-1 checkbox is not marked as affirmative. This means the reported stock option award was not designated as being made pursuant to a Rule 10b5-1 pre-arranged trading plan.

How many derivative securities does the BNGO CSO hold after this option grant?

Following this transaction, Alex Reid Hastie is reported as holding 54,000 stock options directly. These options are all from the newly granted award, with vesting spread between 2027 and subsequent monthly installments over three years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hastie Alex Reid

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	08/03/2026		A		54,000		(1)	08/02/2036	Common Stock	54,000	$0	54,000(2)	D

Explanation of Responses:

1. 25% of the shares subject to the option shall vest and become exercisable on August 2, 2027, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from August 2, 2027, subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each such applicable vesting date.

2. The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)